Sponsor:Cardiac Pacemakers, Inc (dba Boston Scientific)

Study Title:LSS 4-Site

Eligibility requirements:All patients must be > 18 years old and have medical need for (or have already received) a Boston Scientific CRM implantable device system to regulate their heart.

Study objectives:This objective of this study is to collect data on the long-term peformance of this FDA-approved device.

Procedures:

All patients will receive a commercially-available CRM implantable device as per the standard of care for cardiology patients. All patients who receive this device will be offered participation in this study. If a patient agrees, he/she will be followed for device performance for five years.

###

Sponsor:Hansen Medical, Inc.

Study Title:A Prospective, Single Arm Study of the Hansen System for Introducing and Positioning the ThermoCool® Catheter in Subjects with Paroxysmal Atrial Fibrillation.

Eligibility requirements:All patients must be > 18 years old with paroxysmal atrial fibrillation that has not responded to at least one anti-arrhythmic drug. Patients must be willing and able to undergo catheter ablation.

Study objectives:This IDE study is to evaluate the safety and effectiveness rate for the Biosense NaviStar® ThermoCool® catheter remotely introduced and positioned through the family of Artisan guide catheters.

Procedures:

Eligible patients will undergo a catheter ablation utilizing the Sensei X Robotic Catheter System and the family of Artisan guide catheters for introducing and positioning of the ThermoCool catheter. After the ablation, data on the safety and efficacy of the procedure will be collected. Subjects will have follow up evaluation at the following time points: discharge, 7 days, 30 days, 90 days, 180 days, and 360 days after the ablation.

Sponsor:Abbott Cardiovascular

Study Title:ABSORB

Eligibility requirements:All patients must be > 18 years old, have evidence of myocardial ischemia with an ejection fraction > 30%, and no prior acute myocardial infarction or STEMI/NSTEMI to consent to participate.

Once consented, the diagnostic angiogram must reveal one or two de novo lesions of appropriate size to continue on to randomization in the study.

Study objectives:This IDE study is to evaluate the safety and effectiveness of the Absorb BVS System (bioresorbable stent) compared to the XIENCE (metallic stent) in the treatment of subjects, including those with diabetes mellitus, with ischemic heart disease caused by up to two de novo native coronary artery lesions in separate epicardial vessels.

Procedures:All patients will be prepared as per the standard of care for interventional cardiology subjects. Prior to the procedure all subjects will be offered participation in this study.

If a patient consents, during the intervention, if qualifying lesions are identified, then the patient will be randomized 2:1 to receive the ABSORB BVS vs. the XIENCE device.

This is a single-blind study so subjects will not be told what device they received. All subjects will be required to complete Quality of Life questionnaires periodically throughout the study.

Subjects will be required to take anti-platelet medication as per standard of care for any stent placement, and be followed for five years post intervention

Sponsor:St. Jude Medical

Study Title:MULTIPOINT™ PACING (MPP) IDE STUDY

Eligibility requirements:All patients must be > 18 years old and have a clinical indication for implantation of a CRT-D system for treatment of heart failure or life-threatening ventricular tachyarrhythmia(s). To be eligible, patients cannot have a prior LV placement.

Procedures:The implant procedure will be performed according to standard of care. The final LV pacing configuration is programmed using any one of the 10 available pacing vectors. Patients will continue to receive BiV therapy until the 3-month follow-up visit. At the 3-month visit, responder status will be assessed and only patients with “equal or better” echocardiographic measurements (i.e., EA VTI measurements) with MPP feature on compared to BiV pacing will be randomized in a 1:1 ratio to one of the two arms – the (1) BiV arm or the (2) MPP arm. Final programming in both arms will be performed as follows: (1) MPP arm: the physician will program MPP using any combination that yields “equal or better” acute hemodynamics compared to BiV pacing. (2) BiV arm: the final BiV programming will be left up to the physician's discretion. All patients will continue to be followed up at 6 and 9 months, and every 6 months thereafter until the end of the study. At the 9-month visit, responder status will be evaluated once again and compared to the status at 3 months, for the evaluation of the primary efficacy endpoint.

Sponsor:Medtronic

Study Title:REVEAL AF

Eligibility requirements:Patients 18 years of age or older, who are suspected of having Atrial Fibrillation (AF) or at risk of having AF based on symptoms and/or patient population characteristics.

Patients must not have a history of AF, atrial flutter or hemorrhagic stroke. No ischemic stroke or TIA within 1 year of enrollment. No heart attack or heart surgery within 90 days of enrollment.

Study objectives:To determine the prevalence of an AF episode lasting for 6 minutes or more in patients who are at risk of having AF and also identify incidences that can predict AF onset in these patients.

Information will also be gained as to how physicians manage these patients once AF is detected. This study will also explore the Quality of life issues, AF burden over time and determine how patients at high risk of having AF utilize the healthcare that is available to them.

Procedures:All patients will receive and be continually monitored by a REVEAL implantable cardiac monitor (ICM) for the incidence of AF in patients at high risk of developing AF.

Patients will be required to have their device interrogated every month to transmit data over the Medtronic CareLink network for the detection of AF.

There will be scheduled follow up doctor visits at 6, 12 and 18 months after successful implant. Patients will be monitored for a minimum of 18 months and a maximum of 30 months after implantation of the REVEAL cardiac monitor.

Procedures:
Patients will be randomized 1:1 to receive either the conservative or invasive treatment plan. All patients will then be followed via clinic visits and phone calls to provide lifestyle counseling, assess quality of life, and monitor for any future cardiac events.

Sponsor:
St. Jude Medical

Eligibility requirements:
Patients who are at least 18 years old, have an indication for an ICD (Implantable Cardioverter-Defibrillator), and documented coronary artery disease.

Study objectives:
To demonstrate the safety and effectiveness of the Fortify ST ICD system (or other system with the ST Monitoring Feature) by analyzing the sensitivity of the feature to detect clinical events.

Procedures:
Patients will have the ST Monitoring Feature of their ICDs activated and programmed. Each patient will receive a Merlin® @ home transmitter and will be enrolled in the Merlin.net System. This System allows the ICD to transmit ST (a segment of the EKG) information. It can alert the patient or the patient's physician when any change occurs.

###

*Each listing only contains a summary of the study information. Please contact the Principal Investigator or Study Coordinator for the full details on a particular study.